To sum up, S100A16 can promotes osteosarcoma progression by activating the PI3K/AKT signaling pathway through ANXA2, suggesting that the S100A16/ANXA2 axis may represent a novel therapeutic target for osteosarcoma. This evidence concerns the gene AKT1 and osteosarcoma.